+

PE20020300A1 - Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco - Google Patents

Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco

Info

Publication number
PE20020300A1
PE20020300A1 PE2001000807A PE2001000807A PE20020300A1 PE 20020300 A1 PE20020300 A1 PE 20020300A1 PE 2001000807 A PE2001000807 A PE 2001000807A PE 2001000807 A PE2001000807 A PE 2001000807A PE 20020300 A1 PE20020300 A1 PE 20020300A1
Authority
PE
Peru
Prior art keywords
solution
composition
oxazolidinone
acetamide
drug
Prior art date
Application number
PE2001000807A
Other languages
English (en)
Inventor
Sandra M Sims
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of PE20020300A1 publication Critical patent/PE20020300A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA EN SOLUCION QUE COMPRENDE : a)DE 3mg/ml A 100mg/ml DE OXAZOLIDINONA SIENDO LA CONCENTRACION EFICAZ POR ENCIMA DEL LIMITE PRACTICO DE SOLUBILIDAD DEL FARMACO EN UNA SOLUCION SUSTANCIALMENTE ISOTONICA CON UN pH FISIOLOGICAMENTE COMPATIBLE DE PREFERENCIA LINEZOLIDA, N-((5S)-3-(3-FLUORO-4-(4-(2-FLUOROETIL)-3-OXOPIPERAZIN-1-IL)FENIL)-2-OXOXAZOLIDINIL-5-ILMETIL)ACETAMIDA; CLORHIDRATO DE (S)-N-[[3-[5-(4-(PIRIDIL)PIRID-2-IL]-2-OXO-5-OXAZOLIDINIL]METIL]ACETAMIDA; N-[[(5S)-3-[4-(1,1-DIOXIDO-4-TIOMORFOLINIL)-3,5-DIFLUOROFENIL]-2-OXO-5-OXAZOLIDINIL]METIL]ACETAMIDA; b)UN COMPUESTO DE a, ß, g-CICLODEXTRINA, ALQUILCICLODEXTRINAS, HIDROXIALQUILCICLODEXTRINAS DE PREFERENCIA SULFOBUTILETER ß-CICLODEXTRINA UTILIZANDOSE DE 1mg/ml A 500mg/ml; c)UN AGENTE TAMPON O UN AGENTE PARA AJUSTAR LA OSMOLALIDAD. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE INFECCIONES
PE2001000807A 2000-08-22 2001-08-14 Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco PE20020300A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22684600P 2000-08-22 2000-08-22
US28534701P 2001-04-20 2001-04-20

Publications (1)

Publication Number Publication Date
PE20020300A1 true PE20020300A1 (es) 2002-05-10

Family

ID=26920930

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000807A PE20020300A1 (es) 2000-08-22 2001-08-14 Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco

Country Status (20)

Country Link
US (1) US6989381B2 (es)
EP (1) EP1311296B1 (es)
JP (1) JP2004506699A (es)
KR (1) KR20030027047A (es)
AR (1) AR030470A1 (es)
AT (1) ATE312627T1 (es)
AU (2) AU2001285087B2 (es)
BR (1) BR0113363A (es)
CA (1) CA2419597A1 (es)
CY (1) CY1105464T1 (es)
DE (1) DE60115910T2 (es)
DK (1) DK1311296T3 (es)
ES (1) ES2250461T3 (es)
IL (1) IL154423A0 (es)
MX (1) MXPA03001531A (es)
NO (1) NO20030787L (es)
NZ (1) NZ524158A (es)
PE (1) PE20020300A1 (es)
PL (1) PL365674A1 (es)
WO (1) WO2002015940A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
GB0009803D0 (en) 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
US6696426B2 (en) 2000-08-22 2004-02-24 Pharmacia Corporation Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems
WO2004098592A1 (ja) * 2003-05-06 2004-11-18 Senju Pharmaceutical Co. Ltd. オキサゾリジノン誘導体含有組成物
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
JP2013507443A (ja) * 2009-10-13 2013-03-04 リブ−エックス ファーマシューティカルズ,インコーポレイテッド 薬学的組成物
WO2015042170A1 (en) 2013-09-17 2015-03-26 Wayne State University Compositions and uses of combinations of dim-related indoles and selected anti-androgen compounds
WO2018055581A1 (en) * 2016-09-24 2018-03-29 Jodas Expoim Private Limited Stable injectable composition of oxazolidinone
WO2018157043A1 (en) * 2017-02-27 2018-08-30 University Of St. Thomas Oxazoudinones and pharmaceutical compositions thereof for treating bacterial infections, including infection of mycobacterium tuberculosis
CN108571074A (zh) * 2018-05-25 2018-09-25 夏念涛 一种装配式钢结构矩形组合柱框架体系及其装配方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU190818B (en) * 1982-11-09 1986-11-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for producing complexes of piperonyl-butoxide-cyclodextrin
HU194858B (en) * 1982-12-03 1988-03-28 Chinoin Gyogyszer Es Vegyeszet Process for producing dibenzo/b,d/pirane derivatives and pharmaceutical compositions containing them
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
ZA892684B (en) 1988-04-27 1989-12-27 Warner Lambert Co Cyclodextrin complexes of 5-aminohexahydropyrimidine compounds
US5164510A (en) * 1988-09-15 1992-11-17 The Upjohn Company 5'Indolinyl-5β-amidomethyloxazolidin-2-ones
US5231188A (en) * 1989-11-17 1993-07-27 The Upjohn Company Tricyclic [6.5.51]-fused oxazolidinone antibacterial agents
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
ATE196426T1 (de) * 1991-06-21 2000-10-15 Takeda Chemical Industries Ltd Zyklodextrin-zusammensetzung enthaltend fumagillol-derivate
DE69216251T2 (de) * 1991-11-01 1997-05-15 Pharmacia & Upjohn Co., Kalamazoo, Mich. Substituierte aryl- und heteroaryl-phenyloxazolidinone
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
JP2879395B2 (ja) * 1992-10-26 1999-04-05 富士写真フイルム株式会社 ロダシアニン化合物及びシクロデキストリンを含有する抗癌性組成物
ES2062941B1 (es) * 1993-03-15 1995-10-01 Uriach & Cia Sa J Nuevos derivados de azol activos por via oral.
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
NZ274966A (en) * 1993-11-22 1998-01-26 Upjohn Co Substituted-hydroxyacetyl piperazine phenyl oxazolidinone derivatives, use in pharmaceutical compositions
BE1008307A3 (fr) * 1994-06-16 1996-04-02 Europharmaceuticals Sa Sel de nimesulide hydrosoluble, solution aqueuse le contenant, sa preparation et son utilisation.
DE4425612A1 (de) * 1994-07-20 1996-04-04 Bayer Ag 6-gliedrige stickstoffhaltige Heteroaryl-oxazolidinone
DE4425613A1 (de) * 1994-07-20 1996-01-25 Bayer Ag 5-gliedrige Heteroaryl-oxazolidinone
US5807895A (en) * 1994-11-29 1998-09-15 Schwarz Pharma, Inc. Use of prostaglandin E1, E2 or analogs to prevent renal failure induced by medical tests that utilize contrast media agents
CN1075073C (zh) * 1995-02-03 2001-11-21 法玛西雅厄普约翰美国公司 杂芳环取代的苯基噁唑烷酮抗菌剂
ZA962214B (en) 1995-04-10 1996-10-07 Farmarc Nederland Bv Pharmaceutical composition
AU5780696A (en) 1995-06-02 1996-12-18 Takeda Chemical Industries Ltd. Stabilized composition comprising an antiulcerative benzimid azole
US5824668A (en) * 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
GB9601666D0 (en) * 1996-01-27 1996-03-27 Zeneca Ltd Chemical compounds
HUP9600847A3 (en) 1996-04-02 1999-08-30 Human Oltoanyagtermeloe Es Gyo Nonstochiometric compds. of primycins with ciclodextrin derivatives, pharmaceutical compns. contg. the said compds. and process for preparing them
EP0892792B1 (en) * 1996-04-11 2001-11-21 PHARMACIA & UPJOHN COMPANY Process to prepare oxazolidinones
SE9601556D0 (sv) 1996-04-24 1996-04-24 Astra Ab New pharmaceutical formulation of a thrombin inhibitor for parenteral use
DE69807200D1 (de) 1997-02-27 2002-09-19 Novo Nordisk As Inklusionskomplexe in waessriger loesung
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
ATE253941T1 (de) * 1997-06-13 2003-11-15 Cydex Inc Zusammensetzung mit erhöhter lagerstabilität enthaltend cyclodextrin und wirkstoffe oder wirkstoff-vorstufen, die in wasserunlösliche komponenten zersetzt werden
GB9713149D0 (en) 1997-06-21 1997-08-27 Pfizer Ltd Pharmaceutical formulations
CZ20001613A3 (cs) 1997-11-07 2001-12-12 Pharmacia & Upjohn Company Způsob výroby oxazolidinonů
HUP9701945A3 (en) 1997-11-10 2000-04-28 Hexal Ag Pharmaceutical composition for injection containing cyclodextrin and taxoids
AU1598399A (en) 1997-12-01 1999-06-16 Schering Corporation Injectable antifungal formulations
PT1096934E (pt) * 1998-07-14 2005-11-30 Pharmacia & Upjohn Co Llc Oxazolidinonas para tratamento de infeccoes oculares
AR020660A1 (es) * 1998-09-30 2002-05-22 Alcon Lab Inc Composiciones antibioticas para el tratamiento de ojos, oidos y nariz
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
AU780671B2 (en) * 1999-09-13 2005-04-07 Sun Pharma Global Fze Topical treatment for prevention of ocular infections
US6319020B1 (en) * 1999-12-10 2001-11-20 Sonic Innovations, Inc. Programming connector for hearing devices
PE20020044A1 (es) * 2000-06-16 2002-01-30 Upjohn Co Tiazina oxazolidinona
PE20020578A1 (es) * 2000-10-10 2002-08-14 Upjohn Co Una composicion de antibiotico topico para el tratamiento de infecciones oculares

Also Published As

Publication number Publication date
DE60115910T2 (de) 2006-08-17
AU8508701A (en) 2002-03-04
NZ524158A (en) 2004-12-24
DE60115910D1 (de) 2006-01-19
EP1311296B1 (en) 2005-12-14
EP1311296A2 (en) 2003-05-21
AU2001285087B2 (en) 2006-08-03
US20020068720A1 (en) 2002-06-06
AR030470A1 (es) 2003-08-20
CY1105464T1 (el) 2010-04-28
ES2250461T3 (es) 2006-04-16
NO20030787D0 (no) 2003-02-19
NO20030787L (no) 2003-04-03
IL154423A0 (en) 2003-09-17
MXPA03001531A (es) 2003-06-24
CA2419597A1 (en) 2002-02-28
WO2002015940A2 (en) 2002-02-28
JP2004506699A (ja) 2004-03-04
WO2002015940A3 (en) 2003-02-20
PL365674A1 (en) 2005-01-10
ATE312627T1 (de) 2005-12-15
KR20030027047A (ko) 2003-04-03
US6989381B2 (en) 2006-01-24
DK1311296T3 (da) 2006-04-18
BR0113363A (pt) 2004-01-06

Similar Documents

Publication Publication Date Title
PE20020578A1 (es) Una composicion de antibiotico topico para el tratamiento de infecciones oculares
PE20020300A1 (es) Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
NO20062942L (no) Fremgangsmate for fremstilling av en fast, oralt anvendelig farmasoytisk sammensetning
PE20011269A1 (es) DERIVADOS DE 9-(5-HETEROARILTETRAHIDROFURANIL)-PURINA COMO AGONISTAS SELECTIVOS DEL RECEPTOR A2a DE LA ADENOSINA
JP2010527346A5 (es)
UA88938C2 (ru) Твердые фармацевтические формы для перорального введения, которые содержат ривароксабан, с модифицированным высвобождением
CO5700796A2 (es) Composiciones que contienen piperacilina y tazobactam utiles para inyecciones
PE20090123A1 (es) Un derivado heterociclico conteniendo nitrogeno y un farmaco conteniendo el mismo como el ingrediente activo
AP1545A (en) Hydrochloride salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione.
PE20020044A1 (es) Tiazina oxazolidinona
RS51343B (sr) Nova kompozicija i njena upotreba
JP2011530531A5 (es)
JP2010500415A5 (es)
PE20030007A1 (es) Inhibidores de aldosa reductasa del grupo de las piridazinonas
EA200702238A1 (ru) Комбинация, способ и композиция для лечения рака
MEP33308A (en) Benzimidazole derivative and use as angiotensin ii antagonist
CY1106226T1 (el) Μεσυλικο αλας 5-[4-[2-(ν-μεθυλ-ν-(2-πυριδυλ)αμινο)αιθοξυ]βενζυλ]θειαζολιδινο-2,4-διονης
GEP20084306B (en) Antibacterial indolone oxazolidinones, intermediates for their preparation and pharmaceutical compositions containing them
ATE503748T1 (de) Anti-krebs- und antimikrobielle oxazolidinone und analoga
NO20044672L (no) Parenteral, intravenos og oral administrering av oksazolidinoner for behandling av diabetiske fotinfeksjoner
PE20020295A1 (es) Composiciones de oxazolidinona, ampicilina y sulbactam
JP2002520359A5 (es)
GEP20237580B (en) Cyclodextrin-based formulation of a bcl-2 inhibitor
NZ609964A (en) Pharmaceutical compositions
NO20072303L (no) Kombinasjon av N-(3-metoksy-5-metylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazo 1-2-yl]fenyl)pyridin-3-sulfonamid og et mitotisk middel for behandling av kreft.

Legal Events

Date Code Title Description
FC Refusal
FG Grant, registration
FD Application declared void or lapsed
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载